ABOS NASDAQ
Acumen Pharmaceuticals, Inc.
1W: +28.2%
1M: +1.3%
3M: -0.4%
YTD: +12.4%
1Y: +7.6%
3Y: -35.0%
5Y: -83.1%
$2.26
-0.01 (-0.44%)
After Hours: $2.28 (+0.02, +0.88%)
Weekly Expected Move ±11.7%
$2
$2
$2
$2
$2
Credit Risk of going bust: higher than 79% of companies Debt: 13.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.09 (down 96%), Acumen Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $26.3M against a stock market value of $164.2M.
Distance to default 2.66 (Merton model): prices to 2026-10-26, balance sheet 2026-09-30, debt counted $23.3M (short-term plus half of long-term), stock volatility 79.9%; Altman Z'' -24.06. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.09 (down 96%), Acumen Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $26.3M against a stock market value of $164.2M.
Distance to default 2.66 (Merton model): prices to 2026-10-26, balance sheet 2026-09-30, debt counted $23.3M (short-term plus half of long-term), stock volatility 79.9%; Altman Z'' -24.06. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
Articles (1)
0.45
Bullish
2 bullish
2 neutral
0 bearish
Articles (7d)
4
Daily Sentiment (7 Days)
Articles (45)
At a glance: stocks gapping up premarket
Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript
Acumen targets 30% iADRS slowing as Phase II ALTITUDE-AD data due in November
Acumen Pharmaceuticals GAAP EPS of -$0.35 beats by $0.02
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock Has Average Price Target of $7.00 According to Brokerages
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Brokerages Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Target Price at $7.00
BlackRock Inc. Makes New Investment in Acumen Pharmaceuticals, Inc. $ABOS
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
ADAR1 Capital Management LLC Makes New Investment in Acumen Pharmaceuticals, Inc. $ABOS
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
Acumen (ABOS) Q1 2026 Earnings Transcript
Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Earnings Scheduled For May 12, 2026
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Increases By 46.4%
Acumen Pharmaceuticals (NASDAQ:ABOS) Trading 0.7% Higher – Still a Buy?
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Analysts Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Target Price at $7.00
Acumen Pharmaceuticals files to sell 10.83M shares of common stock for holders
12 Health Care Stocks Moving In Friday's Pre-Market Session
Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding
Acumen Pharmaceuticals GAAP EPS of -$2.00 beats by $0.02
Earnings Scheduled For March 26, 2026
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.80 Consensus Price Target from Analysts
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
Daniel Joseph Oconnell Sells 12,941 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock
Matt Zuga Sells 6,888 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock
Daniel Joseph Oconnell Sells 8,143 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Rating of “Moderate Buy” from Brokerages
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus Bolt Biotherapeutics (NASDAQ:BOLT)
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.75 Average Target Price from Analysts